On July 5, 2022 BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB,OTCQB: BVAXF) ("BioVaxys" or the "Company") reported that is proposing to settle an aggregate of approximately $497,000 in debt through the issuance of common shares to be issued at a deemed price of $0.10 per common share (Press release, BioVaxys Technology, JUL 5, 2022, View Source [SID1234616471]). Completion of the debt settlement remains subject to the finalization of definitive documentation and the approval of the Canadian Securities Exchange.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!